185 related articles for article (PubMed ID: 35881043)
41. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q
Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941
[TBL] [Abstract][Full Text] [Related]
42. Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma.
Chahoud J; Gleber-Netto FO; McCormick BZ; Rao P; Lu X; Guo M; Morgan MB; Chu RA; Martinez-Ferrer M; Eterovic AK; Pickering CR; Pettaway CA
Clin Cancer Res; 2021 May; 27(9):2560-2570. PubMed ID: 33441293
[TBL] [Abstract][Full Text] [Related]
43. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
44. Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.
Huang RSP; Haberberger J; McGregor K; Mata DA; Decker B; Hiemenz MC; Lechpammer M; Danziger N; Schiavone K; Creeden J; Graf RP; Strowd R; Lesser GJ; Razis ED; Bartsch R; Giannoudis A; Bhogal T; Lin NU; Pusztai L; Ross JS; Palmieri C; Ramkissoon SH
Oncologist; 2021 Oct; 26(10):835-844. PubMed ID: 34105210
[TBL] [Abstract][Full Text] [Related]
45. Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.
Aggarwal C; Ben-Shachar R; Gao Y; Hyun SW; Rivers Z; Epstein C; Kaneva K; Sangli C; Nimeiri H; Patel J
JAMA Netw Open; 2023 May; 6(5):e2311181. PubMed ID: 37129893
[TBL] [Abstract][Full Text] [Related]
46. Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.
Xing D; Liu Y; Park HJ; Baek I; Tran H; Cheang G; Novo J; Dillon J; Matoso A; Farmer E; Cheng MA; Tsai YC; Lombardo K; Conner MG; Vang R; Hung CF; Wu TC; Song W
Hum Pathol; 2019 Oct; 92():67-80. PubMed ID: 31437519
[TBL] [Abstract][Full Text] [Related]
47. Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma.
Huang RSP; Haberberger J; Murugesan K; Danziger N; Hiemenz M; Severson E; Duncan DL; Ramkissoon SH; Ross JS; Elvin JA; Lin DI
Mod Pathol; 2021 Jul; 34(7):1425-1433. PubMed ID: 33637877
[TBL] [Abstract][Full Text] [Related]
48. Pathogenesis of Penile Squamous Cell Carcinoma: Molecular Update and Systematic Review.
Ribera-Cortada I; Guerrero-Pineda J; Trias I; Veloza L; Garcia A; Marimon L; Diaz-Mercedes S; Alamo JR; Rodrigo-Calvo MT; Vega N; López Del Campo R; Parra-Medina R; Ajami T; Martínez A; Reig O; Ribal MJ; Corral-Molina JM; Jares P; Ordi J; Rakislova N
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008677
[TBL] [Abstract][Full Text] [Related]
49. Comprehensive genomic and immunohistochemical profiles and outcomes of immunotherapy in patients with recurrent or advanced cervical cancer.
Kim YN; Lee K; Park E; Park J; Lee YJ; Nam EJ; Kim SW; Kim S; Kim YT; Lee JY
Front Oncol; 2023; 13():1156973. PubMed ID: 37256181
[TBL] [Abstract][Full Text] [Related]
50. Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma.
Bandini M; Ross JS; Zhu Y; Ye DW; Ornellas AA; Watkin N; Ayres BA; Hakenberg OW; Heidenreich A; Salvioni R; Catanzaro M; Raggi D; Giannatempo P; Marandino L; Haidl F; Pederzoli F; Briganti A; Montorsi F; Chipollini J; Azizi M; De Meerleer G; Brouwer OR; Grass GD; Johnstone PA; Albersen M; Spiess PE; Necchi A
Eur Urol Oncol; 2021 Oct; 4(5):802-810. PubMed ID: 33199252
[TBL] [Abstract][Full Text] [Related]
51.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
52. Immune landscape and immunotherapy for penile cancer.
Tang Y; Hu X; Wu K; Li X
Front Immunol; 2022; 13():1055235. PubMed ID: 36524123
[TBL] [Abstract][Full Text] [Related]
53. Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.
Huang RSP; Carbone DP; Li G; Schrock A; Graf RP; Zhang L; Murugesan K; Ross JS; Tolba K; Sands J; Oxnard GR; Spigel D
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36650021
[TBL] [Abstract][Full Text] [Related]
54. Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study.
Xiao Y; Lu D; Lei M; Xie W; Chen Y; Zheng Y; Wang C; Zhao J; Zhu Z; Zhao X; Huang M; Lin Y; Li Z; Yang L
Ann Transl Med; 2021 Nov; 9(22):1661. PubMed ID: 34988170
[TBL] [Abstract][Full Text] [Related]
55. Profiling of expression of human papillomavirus-related cancer miRNAs in penile squamous cell carcinomas.
Barzon L; Cappellesso R; Peta E; Militello V; Sinigaglia A; Fassan M; Simonato F; Guzzardo V; Ventura L; Blandamura S; Gardiman M; Palù G; Fassina A
Am J Pathol; 2014 Dec; 184(12):3376-83. PubMed ID: 25455689
[TBL] [Abstract][Full Text] [Related]
56. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
57. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Ready N; Hellmann MD; Awad MM; Otterson GA; Gutierrez M; Gainor JF; Borghaei H; Jolivet J; Horn L; Mates M; Brahmer J; Rabinowitz I; Reddy PS; Chesney J; Orcutt J; Spigel DR; Reck M; O'Byrne KJ; Paz-Ares L; Hu W; Zerba K; Li X; Lestini B; Geese WJ; Szustakowski JD; Green G; Chang H; Ramalingam SS
J Clin Oncol; 2019 Apr; 37(12):992-1000. PubMed ID: 30785829
[TBL] [Abstract][Full Text] [Related]
58. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Seiwert TY; Zuo Z; Keck MK; Khattri A; Pedamallu CS; Stricker T; Brown C; Pugh TJ; Stojanov P; Cho J; Lawrence MS; Getz G; Brägelmann J; DeBoer R; Weichselbaum RR; Langerman A; Portugal L; Blair E; Stenson K; Lingen MW; Cohen EE; Vokes EE; White KP; Hammerman PS
Clin Cancer Res; 2015 Feb; 21(3):632-41. PubMed ID: 25056374
[TBL] [Abstract][Full Text] [Related]
59. Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review.
Su X; Zhang J; Fu C; Xiao M; Wang C
Onco Targets Ther; 2020; 13():3319-3324. PubMed ID: 32368090
[TBL] [Abstract][Full Text] [Related]
60. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.
Huang X; He M; Peng H; Tong C; Liu Z; Zhang X; Shao Y; Zhu D; Zhang J; Yin JC; Yang F; Lan C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34011535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
